Cliff Asness's EW Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 2.08 M shares of Edwards Lifesciences Corporation (EW) worth $161.05 M, representing 0.10% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 4.23 M shares. Largest reduction occurred in Q1 2016, reducing 3.64 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +208,818 | Add 0.00% | 208,812 | $15.03 |
| Q2 2013 | +591,780 | Add 0.00% | 591,774 | $11.20 |
| Q3 2013 | -271,860 | Reduce 45.94% | 319,914 | $11.61 |
| Q4 2013 | +60,300 | Add 18.85% | 380,214 | $10.96 |
| Q1 2014 | -316,800 | Reduce 83.32% | 63,414 | $12.36 |
| Q2 2014 | +264,000 | Add 416.31% | 327,414 | $14.31 |
| Q3 2014 | +3.73 M | Add 1138.72% | 4.06 M | $17.02 |
| Q4 2014 | +4.23 M | Add 104.34% | 8.29 M | $21.23 |
| Q1 2015 | +3.32 M | Add 40.05% | 11.61 M | $23.74 |
| Q2 2015 | +2.81 M | Add 24.20% | 14.41 M | $23.74 |
| Q3 2015 | -1.77 M | Reduce 12.31% | 12.64 M | $23.69 |
| Q4 2015 | -3.3 M | Reduce 26.09% | 9.34 M | $26.33 |
| Q1 2016 | -3.64 M | Reduce 38.96% | 5.7 M | $29.40 |
| Q2 2016 | -1.6 M | Reduce 28.02% | 4.1 M | $33.24 |
| Q3 2016 | -514,458 | Reduce 12.53% | 3.59 M | $40.19 |
| Q4 2016 | -1.82 M | Reduce 50.80% | 1.77 M | $31.23 |
| Q1 2017 | -704,046 | Reduce 39.85% | 1.06 M | $31.36 |
| Q2 2017 | -512,625 | Reduce 48.24% | 550,044 | $39.41 |
| Q3 2017 | -157,161 | Reduce 28.57% | 392,883 | $36.44 |
| Q4 2017 | -50,085 | Reduce 12.75% | 342,798 | $37.57 |
| Q1 2018 | +65,460 | Add 19.10% | 408,258 | $46.51 |
| Q2 2018 | +226,320 | Add 55.44% | 634,578 | $48.52 |
| Q3 2018 | +398,754 | Add 62.84% | 1.03 M | $58.03 |
| Q4 2018 | +1.43 M | Add 137.96% | 2.46 M | $51.06 |
| Q1 2019 | +261,654 | Add 10.64% | 2.72 M | $63.28 |
| Q2 2019 | +204,942 | Add 7.53% | 2.93 M | $61.58 |
| Q3 2019 | -572,769 | Reduce 19.58% | 2.35 M | $72.90 |
| Q4 2019 | -232,596 | Reduce 9.89% | 2.12 M | $77.50 |
| Q1 2020 | +200,142 | Add 9.44% | 2.32 M | $62.87 |
| Q2 2020 | -108,950 | Reduce 4.70% | 2.21 M | $67.57 |
| Q3 2020 | -749,599 | Reduce 33.90% | 1.46 M | $79.09 |
| Q4 2020 | -422,552 | Reduce 28.91% | 1.04 M | $89.61 |
| Q1 2021 | -160,631 | Reduce 15.46% | 878,507 | $83.45 |
| Q2 2021 | -187,193 | Reduce 21.31% | 691,314 | $103.57 |
| Q3 2021 | -69,469 | Reduce 10.05% | 621,845 | $113.21 |
| Q4 2021 | +2,754 | Add 0.44% | 624,599 | $129.55 |
| Q1 2022 | -148,559 | Reduce 23.78% | 476,040 | $117.72 |
| Q2 2022 | -20,318 | Reduce 4.27% | 455,722 | $94.60 |
| Q3 2022 | +71,289 | Add 15.64% | 527,011 | $82.63 |
| Q4 2022 | -38,616 | Reduce 7.33% | 488,395 | $74.08 |
| Q1 2023 | +82,192 | Add 16.83% | 570,587 | $81.47 |
| Q2 2023 | -91,339 | Reduce 16.01% | 479,248 | $93.69 |
| Q3 2023 | -209,826 | Reduce 43.78% | 269,422 | $69.28 |
| Q4 2023 | +144,166 | Add 53.51% | 413,588 | $76.25 |
| Q1 2024 | -70,714 | Reduce 17.10% | 342,874 | $95.22 |
| Q2 2024 | -33,755 | Reduce 9.84% | 309,119 | $92.37 |
| Q3 2024 | -163,543 | Reduce 52.91% | 145,576 | $65.99 |
| Q4 2024 | +63,313 | Add 43.49% | 208,889 | $74.03 |
| Q1 2025 | +709,648 | Add 339.72% | 918,537 | $71.18 |
| Q2 2025 | +51,670 | Add 5.63% | 970,207 | $78.21 |
| Q3 2025 | +1.11 M | Add 114.53% | 2.08 M | $77.38 |
Cliff Asness's Edwards Lifesciences Corporation Investment FAQs
Cliff Asness first purchased Edwards Lifesciences Corporation (EW) in Q4 2012, acquiring 208,812 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Edwards Lifesciences Corporation (EW) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Edwards Lifesciences Corporation (EW) was in Q4 2014, adding 8,287,470 shares worth $175.94 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 2,081,346 shares of Edwards Lifesciences Corporation (EW), valued at approximately $161.05 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.10% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Edwards Lifesciences Corporation (EW) was 14,414,910 shares, as reported at the end of Q2 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.